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Abstract
This chapter provides an updated overview of the scientific literature on cardiac pathol-
ogy predisposing to infective endocarditis and the estimated risk associated with selected 
lesion-specific abnormalities, in an era of changing epidemiology and advanced echocar-
diographic imaging. Importantly, with the evolution of modern-era echo, subtle changes 
in valve structure and function are now easily detectable and a proportion of cases of 
apparently ‘normal’ valves involved with IE, may in fact have subtle pre-existing patho-
logical and/or haemodynamic abnormalities. The chapter will have a clinical focus with 
an aim to provide the Physician with up-to-date and practical information on cardiac risk 
factor identification for infective endocarditis.
Keywords: echocardiography, infective endocarditis, risk factors, valvular heart 
disease, congenital heart disease, degenerative valve disease, rheumatic heart disease, 
cardiac pathology, disease incidence, modern-era
1. Introduction
Infective endocarditis (IE) risk is strongly associated with underlying cardiac disease. This 
chapter will review the pathology, mechanisms and estimated risks according to lesion- 
specific groups. Echocardiographic predictors of IE will be discussed along with the increas-
ingly reported occurrence of IE in ‘normal valves’.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Predisposing cardiac disease: a changing epidemiology
Since mid-last century, the epidemiology of IE has continued to change across high-income 
countries (HIC), from predominantly young patients with rheumatic heart disease (RHD) 
to the current era of an ageing population with IE, infrequent RHD and prevalent degenera-
tive valve disease (DVD). A history of acute rheumatic fever (ARF) in patients with IE had 
declined from ~38 to 22.5% in the 30 years up to 1967 [1]. By the 1980s, this had reduced to 6% 
[2]. According to data from the International Collaboration on Endocarditis—Prospective 
Cohort Study (ICE-PICS), DVD is the most common underlying pathology in IE, with sig-
nificant mitral regurgitation (MR) and aortic regurgitation (AR) accounting for 43.3 and 
26.3% of cases, respectively, compared with rheumatic mitral valve, present in only 3.3% 
cases. Prosthetic valve endocarditis (PVE) accounts for up to 22.2% of cases [3], whilst the 
prevalence of cardiac device-related infective endocarditis (CDRIE) has increased along 
with health-care associated IE (HCAIE) [4]. Endocarditis patterns in congenital heart dis-
ease (CHD) have changed due to patients surviving into adulthood with more complex 
disease, the availability of improved surgical techniques and implantation of prosthetic 
material [5, 6].
The 2015 European Society of Cardiology IE management guidelines now consider the fol-
lowing cardiac conditions to pose the highest risk of IE: (i) prosthetic cardiac valves and/or 
repairs with prosthetic material, (ii) previous IE, (iii) cyanotic CHD, and (iv) any CHD that 
has been repaired for up to 6 months post procedure or indefinitely if a residual defect or 
valve incompetence persists. Repair or intervention includes both surgical and transcatheter 
procedures. Antibiotic prophylaxis is recommended for these patients when exposed to pro-
cedures considered high-risk [7].
3. Estimating risk of infective endocarditis: methodological issues
There are methodological challenges with investigating risk of acquiring IE. Two major limi-
tations are: i) low incidence of IE in the general population and ii) selection bias associated 
with tertiary referral hospitals. Variations in study design and methodology also contribute 
to the difficulties faced in drawing generalised conclusions.
4. Pathogenesis of infective endocarditis with underlying cardiac 
disease
The major predisposing categories of underlying cardiac pathology are DVD, CHD and 
RHD. Platelet-fibrin aggregates form on damaged or inflamed endothelium, resulting in 
nonbacterial thrombotic endocarditis (NBTE), a precursor of IE [8]. Microorganisms are 
able to attach to this nidus via adhesion molecules and stimulate a host inflammatory 
response [8].
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Regurgitant valves are at higher risk of IE than stenotic valves [9]. In a large clinical-pathological 
study on native valve endocarditis (NVIE), 84% of valves were regurgitant [10]. Another 
found the majority of cases of IE presenting to surgery were for regurgitant valves compared 
to a control-group of non-IE cases undergoing surgery (9% of regurgitant bicuspid aortic 
valves (BAV), 1.2% of calcified BAVs, 1.6% of calcified trileaflet aortic valves (AV) and 7% 
of mitral valve prolapse (MVP)) [11]. Aortic regurgitation (AR) is a predisposing lesion in 
17–36% of cases of IE, whilst mitral regurgitation (MR) accounts for 10–18% [12].
The pathogenesis of IE in structural cardiac abnormalities is characterised by the hydrody-
namic theory [13]. A high velocity turbulent jet exerts a shearing effect on endothelium, at the 
site of a restrictive orifice (e.g. ventricular septal defect (VSD) or MR jet) and/or a distal point 
of contact (jet lesion). The narrowest diameter of flow is the vena contracta (VC), just distal to 
the restricted anatomical orifice. This is where the pressure is minimal and retrograde flow 
may occur, permitting platelets and bacteria to deposit [13]. The typical location of vegetation 
is on the upstream side of the valve, that is, the atrial aspect of the MV, tricuspid valve (TV) 
and ventricular aspect AV, pulmonary valve (PV) [9].
Structurally normal native right-sided valves in the absence of significant pulmonary hyperten-
sion, are exposed to lower pressure flows and are far less commonly involved with IE. In children, 
without CHD, native right-sided IE involving normal valves is rare but may occur in association 
with trauma to the valve from central lines or catheters [14, 15]. Other factors are important in risk 
of acquiring IE and include an interplay between microorganism virulence, altered host defence 
mechanisms, predisposing systemic illness, and environmental and social factors [16].
5. Structurally normal native cardiac valves
Infective endocarditis does occur in some patients without pre-existing known structural 
abnormalities. Whether the valves were completely normal is uncertain. Early degenerative 
changes can be present without clinical detection [17]. Modern-era echo with high image reso-
lution and careful scrutiny of valve morphology and function, has the potential to shed more 
light on this research question.
There is an increasing prevalence of IE involving structurally normal cardiac valves, account-
ing for 26–43% of native left-sided IE cases [2, 18, 19]. Sun et al. [18] reported the commonest 
underlying cardiac predisposition was mitral valve prolapse (MVP) followed by normal 
valves (26%). Olmas et al. [20] found in an IE cohort, normal left-sided native valves in 39.8% 
of patients aged >65 years and in 53.8% of those aged ≤65 years, whilst DVD comprised 23.4% 
of the cohort. However, details regarding Doppler valve function were not available. This 
is important, for even normal valves may be regurgitant, exposing endothelium to shear-
ing forces. Limitations include assessing valves for pre-existing pathology when already 
involved by infection and absence of pathological correlation to exclude subtle underlying 
pathology. In vitro studies have demonstrated certain microorganisms can attach to and/or 
be internalised by healthy valve endothelium, however in vivo, animal studies have required 
trauma to the endothelium to initiate IE following an inoculum of bacteria [9]. This raises the 
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question—are the valves ‘normal’ or are there subtle pathological changes or haemodynamic 
disturbance, which predispose to IE. This was also raised by Que and Moreillon [21] and 
Baddour et al. [9].
To assess normal valve thickness according to age, 200 normal valves were reviewed at 
autopsy [22]. There was approximately double the thickness of the aortic cusps and mitral 
leaflets with age [22]. In a separate study, transoesophageal echo (TOE) identified normal MV 
thickness overall to be ≤3 mm and AV≤2 mm in those aged <60 years [23]. The prevalence of 
normal valves with physiological regurgitation was investigated in a retrospective echocar-
diographic study of 1333 patients without a history of cardiac disease or hypertension [24]. 
Physiological MR and TR were defined as structurally normal valves on 2-D imaging, with 
a regurgitant jet area occupying <20% of the left atrial (LA) area and <5 cm2 within the right 
atrium (RA), respectively. Aortic regurgitation with jet to LVOT width ratio <25% and normal 
leaflets was considered physiological. Non-organic MR was detected in 1/3rd or patients aged 
10–19 years and approximately 2/3rd of persons aged >30 years. Non-organic TR was identi-
fied in over 4/5th of persons across all age cohort groups (10–89 years). Non-organic AR was 
present in <10% of patients under 50 years, with an increase in prevalence corresponding to 
each decade, up to 46% of those aged 80–89 years [24].
5.1. Risk of endocarditis in normal valves with physiological regurgitation
Data is not readily available on the risk of IE in patients with left-sided non-organic regurgita-
tion. However, one study did assess the risk of IE in structurally normal right-sided cardiac 
valves in adult patients with CHD and pulmonary hypertension (PHTN) [25]. Both TVs and PVs 
had physiological regurgitation. The presence of PHTN was responsible for increased regurgi-
tant velocities across the valves and thought to mimic the haemodynamic forces experienced by 
incompetent left-sided valves. High velocity flow was defined as PR jet ≥3.2 m/s and TR≥4.7 m/s. 
A small subset of valves was inspected at necropsy with the majority of TVs and minority of 
PVs revealing mild nodular degenerative changes along leaflet closure margins. The echocar-
diograms were said to be normal in appearance. There were 0.61 and 7.17 cases of IE per 1000 
patient-years in the normal valve group compared to the CHD control group, respectively. The 
risk was therefore small, but inconclusive due to insufficient patient numbers [25].
6. Degenerative valve disease
6.1. Degenerative disease of the aortic valve
The prevalence of nonrheumatic AS increases with ageing [26]. In a cohort of older patients 
with IE, the prevalence of acquired MR and AS was reported as 57 and 28% respectively, com-
pared with 38 and 10% in patients <65 years [26, 27].
6.1.1. Fibro-calcific degeneration
Age-related findings often begin on the aortic valve in early or middle adulthood and include 
the following: (i) noduli arantii—fibroelastic proliferation on the ventricular surface of the 
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cusps, from early adulthood, most pronounced on the noncoronary cusp, (ii) ridge-like thick-
ening at the base of cusps where mechanical forces are highest; occurs in early adulthood 
in 20–40% persons, and (iii) commissural adhesion, due to fibroelastic hyperplasia, affecting 
10–20% of older persons [28]. With ageing, endothelial dysfunction and hemodynamic stress 
lead to degenerative changes, inciting an inflammatory process, not unlike atherosclerosis. 
Histological changes include subendothelial thickening, lipid and protein accumulation, 
inflammatory cell proliferation, fibrosis and calcification within the valve fibrosa [29]. The 
process is accelerated over the age of 55 years, and onset in males is marginally earlier than 
females [28]. Initially there is no significant restriction to cusp opening and the diagnosis of 
aortic sclerosis is confirmed with echo.
6.1.1.1. Aortic sclerosis and echocardiography
The presence of aortic sclerosis (focal thickening, no commissural fusion, peak velocity 
<2.0 m/s) is associated with an increased risk of death [30]. Caution should be exercised 
not to over diagnose sclerosis on echo [31]. Artefactual thickening and echogenicity can 
appear with harmonic imaging and over-gained signals. Optimising transthoracic (TTE) 
image settingsand use of both harmonic and fundamental frequencies can overcome these 
limitations [31]. Transoesophageal imaging has higher resolution and anatomical detail is 
superior [31].
6.1.1.2. Aortic stenosis and risk of endocarditis
Eventually large calcified deposits occupy the body of the leaflet and can extend into the ven-
tricular septum, the ventricular surface of the anterior mitral valve leaflet (AMVL) and are 
associated with mitral annular calcification (MAC). Cusp motion becomes restricted and aortic 
stenosis (AS) ensues. Ulcerations and thrombi may form, being a potential mimicker of IE 
[16, 32], and may form a nidus for infective endocarditis. There is a paucity of data on IE occur-
ring with aortic sclerosis, although empirically, the risk is very small. Endocarditis of calcific 
trileaflet AS is relatively uncommon. According to Delahaye [33] 27/366 cases of native valve 
IE were pure AS. Risk is higher in patients with BAV and/or AR. In a study from the Mayo 
clinic [10], 310 native valves were excised for IE and it was reported 59% had no calcification. 
Mild-moderate and severe calcification was present in 37% and 5%, respectively. The most 
common underlying cardiac structural abnormalities were BAV (38% of 170 aortic valves) and 
MVP (43% of 120 mitral valves). This finding would suggest that IE is less common in severely 
calcified valves [10]. Another study with pathologic correlation found pre-existing calcification 
present in 27% of valves with IE, though numbers in the study were small [11].
Acquired degenerative changes of the AV leaflets can occur secondarily in the context of con-
ditions leading to annuloaortic dilatation. In this pathology, the leaflets come together at the 
free edges rather than the zone of coaptation, leading to focal thickening, and increased risk 
of NBTE and IE [17].
6.1.1.3. Fenestrations
Acquired age-related fenestrations form within the lunular region of the aortic semilunar 
cusps, adjacent to the commissures, often in association with myxomatous AV disease. 
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Fenestrations are found in approximately 5% of females and 10–20% of males, mostly present 
from the age of <45 years with a minor increase in prevalence over time, in males [28]. 
They are not routinely identified on echo because of their location above the line of closure. 
Fenestrations result in valvular regurgitation in the following circumstances: (i) spontaneous 
rupture resulting in a flail cusp, (ii) fenestration enlarges to extend below the zone of coapta-
tion and/or (iii) reduced leaflet coaptation, such as prolapse or root dilatation, when the fenes-
tration is no longer ‘sealed-off’ within the cusp closure zone [34, 35]. The risk of IE associated 
with fenestrations or valvular perforations is unknown.
6.1.1.4. Lambl’s excrescences
Lambl’s excrescences increase in prevalence with age and may become incorporated into the 
noduli arantii [28]. They are located along the lines of cusp closure of left-sided (high pres-
sure) valves. They are composed of a fibro-elastic core with an endothelial layer covering the 
surface. There is associated turbulence and relative stasis of blood flow, which predisposes to 
formation of NBTE and IE [34]. Although the risk of IE is unknown, empirically it is uncom-
mon. Occasionally Lambl’s excrescences can mimic vegetation and lead to a false-positive 
diagnosis of IE. However, Lambl’s are usually identified as thin single or multiple filamen-
tous strands on echo, which help differentiate them from typical vegetations and papillary 
fibroelastomas.
6.1.2. Myxomatous degeneration
Primary myxomatous degeneration (PMD) of the AV is less common than of the MV. In 
cases of significant ‘pure’ AS, it has been said to be the primary underlying pathology in up 
to 10–36% of subjects [38], however other pathological studies examining excised regurgi-
tant aortic valves have reported much lower rates of PMD, at 2% [36] and in a more recent 
clinicopathological correlation study from China, 3% (35 of 1080 excised aortic valves) 
[37]. Histological findings include degeneration of the fibrosa layer, disruption of collagen 
fibres and deposition of mucopolysaccharides [37]. The cusps are susceptible to developing 
fenestrations adjacent to the commissures and with time, the prolapsing cusps develop thick-
ening of the free margin, thought secondary to chronic trauma from the regurgitant jet [38]. 
The incidence of endocarditis with this pathology is unknown, however empirically, high 
velocity regurgitant jets increase the risk of IE.
6.2. Degenerative disease of the mitral valve
6.2.1. Mitral valve sclerosis and age-related changes
Mitral valve sclerosis is commonly encountered in the elderly and characterised by leaf-
let thickening. In patients >60 years, the leaflets are at least twice the thickness compared 
to early adulthood [22]. The following changes are frequently noted on the anterior leaf-
let: (i) senile sclerosis - nodular thickening on the atrial surface of the closing edge, up to 
age of 65 years, (ii) atheromatosis—age-related lipoid deposition (yellow plaque) on the 
ventricular aspect of the base of the leaflets extending towards and sometimes involving 
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the chordal apparatus [28]. The following changes may be noted at the posterior leaflet: (i) 
puckered scars—infrequent at 3–5%, > 65 years, (ii) fibro-elastic hyperplasia (mitral opac-
ity) of the atrial surface in ~20%, >65 years and, (iii) mucoid or myxomatous degeneration 
(~ 5–10%) ± prolapse, with increased proteoglycans in the spongiosa layer [28]. The condition 
shows a slight increase with age in the milder forms. Severe forms of mucoid change were not 
related to age [28]. Fibroelastic deficiency (FED) is seen more commonly in the elderly and can 
lead to leaflet prolapse and/or chordal rupture.
Mitral annular calcification (MAC) is common in the elderly though can occur prematurely 
in certain other conditions such as hypertrophic cardiomyopathy (HCM), PMD, diabetes and 
renal disease. MAC commonly involves the posterior annulus and parallels AV calcification, 
with a sharp rise >55 years [28]. Normal sphincteric action of the annulus is altered and MR 
ensues [17]. Inflammation accompanies MAC and complications such as ulcerative erosion, 
thrombus formation, systemic embolic, liquefaction necrosis, infected vegetations and abscess 
formation occur with increased frequency [34, 39]. With large protruding MAC deposits, it is 
theorised there is alteration of local blood flow, predisposing to NBTE and IE [39]. Mitral ste-
nosis can also occur as calcium encroaches on the leaflets. Vegetations form at the base of the 
mitral leaflet [39] rather than the leaflet closure line, as seen with typical regurgitant lesions 
[17] and are localised accurately with 3-D echo. Although MAC predisposes to IE, the exact 
risk is unknown.
6.2.2. Myxomatous mitral valve disease and prolapse
Mitral valve prolapse (MVP) most commonly occurs due to PMD. Secondary myxomatous 
degeneration can occur in other conditions, such as RHD and age-related degeneration. 
Additional causes of prolapse include congenital and papillary muscle dysfunction. The 
‘middle’ tissue layer of healthy valves, the spongiosa, normally thickenings towards the 
leaflet/cusp margins and this is not a pathological finding [16]. With pathological myxoma-
tous changes, there is diffuse increase in deposition of glycosaminoglycans in leaflets, cusps, 
chords and annuli and thrombi may form [16]. In a study from China, echocardiography 
(either TTE or TOE) correctly identified valve prolapse and thickening in 85% of patients in 
which myxomatous disease was confirmed pathologically [37].
6.2.2.1. Prevalence of mitral prolapse and regurgitation in healthy individuals
In a landmark study, data was collected from a healthy population comprising the offspring 
of the original Framingham study group [40]. Echocardiographic criteria (2-D) used in the 
study were as follows: (i) prolapse - superior displacement of the mitral leaflet(s) >2 mm 
above the atrioventricular annular plane in the long-axis window, (ii) classic MVP - at least 
2 mm prolapse with leaflet thickness ≥5 mm and, (iii) non-class MVP – ≥2 mm prolapse with 
leaflet thickness <5 mm [40]. A total of 2.4% met criteria for prolapse. Classic MVP was found 
in 1.3% of persons and non-classic MVP in 1.1% [40], with mean age mid 50s and a slight 
female preponderance. Mean MR volume was mild in the classic group and a trace in the non-
classic and control groups. Severe MR was only found in the classic groups and comprised 
7% of cases [40].
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Overall incidence of IE 
in MVP (risk per 1000 
patient-years)
MVP with regurgitation 
(risk per 1000 patient-years)
Overall incidence of IE in MVP 
with murmur (risk odds ratio 
– ‘OR’)
Katan et al. [41] 0.87 0.631; 2.92; 7.163
Clemens et al. [42] and 
Tay and Yip [43]
0.38 n/a 15.1
Retchin et al. [44] 0.3 n/a n/a
Hickey et al. [45] 0.14 n/a 5.3
Danchin et al. [46] n/a n/a 14.5
1Less than moderate MR.
2At least moderate MR.
3Flail leaflet.
Table 1. Risk of infective endocarditis associated with mitral valve prolapse and regurgitation.
6.2.2.2. Prevalence and risk of mitral prolapse in endocarditis
Mitral valve prolapse occurs in 7–30% of cases of native valve IE, nearly always in the pres-
ence of MR and associated with redundant leaflets. Of note, NBTE forms on atrial aspect 
of thickened, redundant leaflets [17]. In a large clinicopathological correlation study of 120 
native mitral valves excised due to IE, 43% had a history of prolapse [10]. The estimated risk of 
IE is shown in Table 1. Recent data published by Katan et al. [41] found a higher incidence of 
IE in MVP compared to earlier publications, thought in part due to the previous overestima-
tion of true MVP in healthy individuals using less stringent diagnostic methods [41].
6.2.2.3. Mitral prolapse—echocardiographic predictors of endocarditis risk
Mitral regurgitation confirmed on echo and/or typical murmur, has been shown to be a pre-
dictor of risk in studies that have specifically assessed this variable (Table 1). In the study by 
Katan et al. [41], no cases of IE occurred in patients without a history of MR during follow-up. 
Nishimura et al. [47], found redundant leaflets (i.e. M-mode thickness ≥5 mm) were associated 
with IE, though numbers were small. Marks et al. [48] also confirmed classic MVP with leaflet 
thickening ≥5 mm (2-D echo) and redundancy was associated with IE risk over non classic MVP.
6.3. Degenerative disease of the right-sided cardiac valves
Gross degenerative changes of the right-sided valves are uncommon compared to the higher-
pressure environment of left-sided valves. The TV often undergoes only minimal change, with 
nodular thickening along the closing edge of the anterior valve leaflet. Mild diffuse leaflet thick-
ening may occur in middle age; though in a minority of patients (>65 years), may become moder-
ate or severe [28]. Myxoid degeneration of TV leaflets occurs occasionally [49], with TV prolapse 
(TVP) and PMD occurring in about 4% of cases [37, 40] . The risk of IE in TVP is unknown.
The pulmonary valve (PV) remains translucent and thin in the vast majority. Nodular thick-
ening (noduli Morgani) along the centre part of the closing margin occurs in <50% of subjects, 
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increasing gradually with age [28]. The mild age-related degenerative changes of the PV are 
not typically associated with IE.
7. Congenital heart disease
7.1. Overall incidence of endocarditis in congenital heart disease
Recently published research estimates the incidence of adult congenital heart disease (ACHD)-
associated IE is 1.0–1.33 cases per 1000 patient-years and in children (0–18 years), 0.41 cases 
per 1000 patient-years. Cumulative first incidence of IE, from birth to 18 years, was shown to 
be 6.1/1000 [5, 50, 51]. According to published data from the USA, the estimated incidence in 
children is lower, at 0.05–0.12 cases per 1000 patient-years [52, 53]. Interestingly, Marom et al. 
found 18% of children with IE had no underlying structural heart disease and no identifiable 
risk factors, compared to earlier published rates, ranging from 2.5–19% [54].
7.2. Incidence of endocarditis in complex congenital heart disease
Incidence rate in complex CHD has recently been published by Kuijpers et al. [5], 2017. 
Incidence of IE (per 1000 patient-years) reported according to lesion-specific pathology include: 
pulmonary atresia (PA) with ventricular septal defect (VSD), 7.84; double outlet right ventricle 
(DORV), 3.59; Marfans, 2.35; univentricular heart (UVH), 1.9; Tetralogy of Fallot (ToF), 1.8; con-
genitally corrected transposition (cTGA), 0.93; transposition, 0.89; and Ebstein’s anomaly, 0.7.
7.3. Endocarditis in simple shunts
7.3.1. Ventricular septal defect
Overall estimated incidence of IE with a VSD in ACHD is 1.0–1.33 and for children, 0.41 per 
1000 patient-years (Table 2). In another study, the incidence was reported at 1.86 in adults 
and 1.06 in children, per 1000 patient-years (p = 0.06) [55]. The majority of studies have identi-
fied the following risk factors: i) unrepaired VSD ii) co-existent AR and, iii) residual defect at 
site of VSD repair. It has not been unequivocally proven a restrictive defect carries a higher 
risk. A VSD associated with AR carries a 2x relative risk (incidence increase from 1.25 up to 
3.48/1000) [55], whilst a VSD that has undergone secondary aneurysmal transformation to 
form a Gerbode defect (LV-LA shunt) carries a risk of 5 per 1000 patient-years [56]. In one 
study, non-operated VSD’s carried a 2.6x risk (0.73 versus 1.87/1000 patient-years) [55].
7.3.2. Atrial septal defect
Secundum ASD IE incidence is estimated at 0.23 for children and 0.28–0.64/1000 patient-years 
in adults (Table 2). A higher than expected risk was likely due to concomitant valve dis-
ease or misdiagnosed primum defects [50]. Isolated ASD is rarely associated with infective 
endocarditis [57]. The risk in adults with atrioventricular septal defect (AVSD) is estimated at 
0.89 per 1000 patient-years (Table 2).
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CHD ASD; 
VSD; 
AVSD; 
PDA
Left-sided1 
Right-
sided2
Cyanotic (complex/conotruncal)3 
Cyanotic (conotruncal/single 
ventricle)4
Kuijpers et al. [5] (ACHD; 
Included prosthetic 
valves)
Incidence (per 
1000 pt. years)
1.33 0.64;
0.82;
0.89;
0.0
1.89;
0.57
1.94
n/a
Adjusted HR 
(95% CI)
n/a n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
Mylotte et al. [51] (ACHD; 
Excluded prosthetic 
valves; Included conduits 
and repairs)
Incident IE (per 
1000 pt. years)
1.0 0.28;
0.65;
n/a;
0.24
1.61;
0.35
n/a
1.17
Adjusted
OR5,
(95% CI)
n/a n/a;
2.81 
(1.87–4.21);
n/a;
n/a
5.11 
(3.6–7.25);
n/a
n/a
4.82 (3.12–7.46)
Rushani et al. [50], 
(Paediatric)
Incidence (per 
1000 pt. years)
0.41 0.23;
0.24;
n/a;
0.35
0.44;
0.29
n/a
2.07
Adjusted
Rate Ratio
(95% CI)
n/a n/a;
0.97 
(0.56–1.66);
n/a;
1.25 
(0.5–3.13)
1.88 
(1.01–3.49);
1.22 
(0.52–2.86)
n/a
6.44 (3.95–10.5)
1Left-sided includes: coarctation, aortic and mitral disease (Mylotte et al. and Rushani et al.); or LVOTO (left ventricular 
outflow tract obstruction), Marfan, BAV, CoA, MV defect, other LVOT (Kuijpers et al).
2Right-sided includes: Ebstein, anomaly of pulmonary artery/valve, TV disease (Mylotte et al. and Rushani et al); or 
Ebstein, RVOTO (right ventricular outflow tract obstruction), other (Kuijpers et al).
3Cyanotic (complex/conotruncal) includes: PA + VSD, DORV, UVH, ToF, TGA, Other (Kuijpers et al).
4Cyanotic (conotruncal/single-ventricle): ToF, TGA, truncus, hypoplastic left heart and univentricular heart (Mylotte 
et al. and Rushani et al.)
5Odds ratio when referenced to ASD, PDA, R-sided groups.
Table 2. Contemporary estimates of incidence and risk hazard ratios for infective endocarditis in children and adults 
with congenital heart disease, across selected lesion-specific groups.
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7.3.3. Ductus arteriosus
The estimated risk of IE with patent ductus arteriosus (PDA) is 0.24 and 0.35 per 1000 patient-
years in adults and children, respectively, whilst other data have shown for an unrepaired 
PDA, the IE risk is 0.35–1.4 per 1000 patient-years, in a mixed adult and paediatric cohort [12, 
50]. According to one study, the risk of IE was only present <4 years of age, likely due to liga-
tion procedure essentially eliminating IE occurrence in older children [50].
7.3.4. Echocardiography
Echo assessment of a VSD should include identification of vegetations or other IE complica-
tions, whether involving the defect, the valves or mural endocardium. Also, imaging must 
define shunt anatomy, efficacy of closure (where present), cardiac chamber size and function, 
pulmonary artery pressure and haemodynamics. Aneurysmal formation and Gerbode defect 
should be excluded. Echo is fundamental in the routine and peri-procedural assessment of 
ASD and other shunts. It is also important to note the presence or absence of an ASD (or other 
shunt) in valvular endocarditis. For example, an infected TV may be a source of paradoxical 
embolism. The direction of the regurgitant jet and shunt, along with the size and mobility of 
a vegetation are important factors when assessing the risk of embolisation.
7.4. Bicuspid aortic valve and aortic coarctation
Bicuspid aortic valve (BAV) is a common congenital abnormality and undergoes accelerated 
degenerative change and dystrophic calcification [17]. Only a minority develop ‘pure’ regur-
gitation. Prevalence of BAV is as high as 1–2% of the population, more common in men and a 
pre-existing lesion in approximately 20% of cases of IE [12]. The estimated hazard ratio (HR) 
for adults with a BAV, of acquiring IE up to middle age is 6.3 (CI, 3.0–13.4), with an incidence 
of approximately 2 per 1000 patient-years [5, 58]. According to Kiyota et al. [59], BAV carries 
a relative risk (RR) of 23.1 times that of a tricuspid aortic valve for acquiring IE. With aortic 
coarctation (AoC), the incidence of IE is <1 per 1000 patient years [12, 58]. At 25 years out, the 
cumulative incidence of IE in another study was 3.5% (563 pts. with median age at time of 
surgery, 1.9 years) [60].
7.5. Congenital aortic stenosis
Incidence of IE in congenital aortic stenosis is estimated at 2.0–2.71 per 1000 patient-years 
[12, 61]. Echocardiographic predictors of risk of endocarditis include AV gradient and a non- 
statistically significant increase in the presence of regurgitation. In the Second Natural History 
Study (NHS-2), Gersony et al. [55], found patients with peak gradient (PG) across the aortic 
valve of <50 mmHg had an IE rate of 0.45 per 1000 person-years versus 5.44 per 1000 person-
years in those with gradient ≥50 mmHg. When the stenotic valve was associated with aortic 
regurgitation (AR), rates of IE increased from 1.98 up to 3.43 per 1000 patient-years (not statis-
tically significant, p = 0.105) [55]. In those managed medically and with a PG < 50 mmHg, the 
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risk of IE was 0.27 per 1000 person-years and for patient with aortic valve replacement (AVR), 
follow-up rate of IE was 1.53 per 1000 person-years [55]. In a different study, the cumulative 
risk was 13.3% out to 25 years post-surgery (median age of surgery 7.0 years) in patients 
where follow-up was available. This equates to a higher annualised incidence of 7.2 per 1000 
patient-years [60].
7.6. Pulmonary valve and tetralogy of Fallot
Pulmonary stenosis (PS) is usually related to congenital valve stenosis, sometimes in asso-
ciation with genetic syndromes. Pulmonary regurgitation (PR) due to congenital disease is 
mostly seen following previous repair of ToF or valvotomy [62]. Endocarditis of the PV is 
relatively uncommon both pre and post-surgery [55, 57, 60], except in palliative shunts [60]. 
In PS, a rate of 0.09 per 1000 person-years has been reported [55]. Tetralogy of Fallot carries a 
risk of approximately 1–2.3 per 1000 patient-years [12, 58].
7.7. Post-surgical and catheter intervention
In the Kuijpers et al. study [5], the following were noted: (i) 8 cases of IE with closed ASD, but 
of those, 6/8 were associated with a valve abnormality; (ii) 13 cases of IE with VSD, where 9/13 
were open, and (iii) no cases of IE with PDA (83.6% were closed). A large population-based 
registry study of children who underwent surgical repair of congenital heart lesions reported 
no patient developed IE after surgical repair of PDA (620 patients, median age 2.6 years) and 
likewise in an ACHD population, no IE was reported [58]. The annualised risk of IE post 
repair of AoC has been estimated at 1.2 per 1000 patient-years [60]. Very uncommonly, early 
(<6 months) IE occurs after closure. Late onset IE is very rare and is usually due to delayed 
endothelialisation [63–65]. In fact, in a surgical follow-up study by Morris et al. [60], no children 
who underwent repair of an isolated secundum ASD developed IE following surgery. Small 
numbers were seen with primum ASD and complete AVSD. After 6 months post-surgical 
closure of ASD, VSD and PDA, the risk of IE is virtually eliminated. The same holds true for 
transcatheter closure, although with residual defects, the risk is not eliminated [52]. After 
definitive surgical repair of ToF, the risk is estimated at 0.7 per 1000 patient years but is much 
higher for a palliative shunt, at 8.2 per 1000 patient-years [60].
In a study by Rushani et al. [50], from the age of 0–6 months, unoperated cyanotic disease had 
an adjusted rate ratio (using ASD as a reference) for IE of 7.56, compared with the operated 
group at 9.22. For unoperated left-sided cardiac lesions, the rate ratio of IE was 2.35, though 
data was insufficient in the operated group to calculate the ratio [50].
In one study, the risk of IE was 5x increased early (<6 months) after any cardiac surgery in 
children [50] and 9.07x increased in adults up to 6 months after any non-valvular cardiac sur-
gery [51]. Kuijpers et al. [5] reported valved-prosthetics in ACHD carry a hazard ratio (HR) 
of 17.29 (at 6 months), 15.91 (6-12 months) and 5.26 (>12 months) post-surgery. Non-valve 
containing prosthetics and repairs were associated with a HR of 3.34 at 0–6 months but no 
increase risk >6 months. The current European endocarditis prophylaxis guidelines (referred 
to elsewhere in this chapter) and US guidelines, accordingly recommend antibiotic prophy-
laxis for 6 months after complete closure of a defect with prosthetic material, regardless of 
whether it be percutaneously or surgically treated [57, 61].
Advanced Concepts in Endocarditis28
8. Hypertrophic cardiomyopathy
8.1. Pathophysiology and diagnosis
Hypertrophic cardiomyopathy (HCM) is an inherited genetic disorder characterised by myocar-
dial thickening. Often this is asymmetric with marked involvement of the ventricular septum. 
In this setting, increased gradients are generated through the left ventricular outflow tract 
(LVOT) and if sufficient, result in systolic motion of the anterior mitral leaflet (SAM). Repeated 
trauma from contact between endocardial surfaces, results in formation of plaques on the 
ventricular septum, at the point of contact with the MV leaflet. There are altered mechanical 
and haemodynamic forces acting on the MV, AV and LVOT. This predisposes to endothelial 
trauma and inflammation, with the potential formation of NBTE and IE at multiple sites [17].
8.2. Echocardiographic diagnosis and predictors of endocarditis risk
Modern echocardiography is readily utilised to diagnose hypertrophic obstructive cardiomy-
opathy (HOCM). Typical criteria include an unexplained septal thickness of ≥15 mm and LVOT 
obstruction as a resting or provoked gradient of ≥30 mmHg. In one study [66], the incidence 
of IE was 1.4 per 1000 patient-years. Echocardiographic predictors of IE risk included: (i) rest-
ing LVOT obstruction with incidence of 3.0 per 1000 patient-years, and (ii) marked left atrial 
dilatation (in presence of resting LVOT obstruction) with incidence of 9.2 per 1000 patient-
years. Left ventricular wall thickness was not associated with increased risk [66].
There is overall conflicting data, with some studies finding IE is related to LVOT gradient and 
a propensity for MV infection, whilst other studies have found the contrary, with no particu-
lar relation to LVOT gradient or predilection for AV or MV [67].
9. Postinflammatory valve disease
9.1. Background and pathologic changes
The most common type of postinflammatory valve disease occurs as a sequela of rheumatic fever, 
leading to RHD. As discussed earlier in this chapter, the incidence has dramatically reduced in 
high-income countries, except in certain indigenous populations and remains a major global 
health burden across middle and low-income countries. In Australia, the estimated rate of ARF 
in young indigenous Australians aged 5–14 years is 150–380 per 100,000 person-years [68].
Rheumatic AV changes include thickening of the cusps, extending to the free margins and 
associated with commissural fusion. Calcification may eventually develop and occurs pre-
dominantly at the commissures and cusp margins. Concomitant changes at the MV are usual 
and involve thickening and retraction of the leaflets and chords along with commissural 
fusion. With ‘pure’ aortic regurgitation, there is cusp fibrosis with leaflet retraction. Fusion 
of the cusps may mimic a congenital BAV and a ‘fish mouth’ appearance of the MV on echo. 
Systemic lupus erythematosus and other inflammatory and autoimmune conditions can 
mimic rheumatic changes [16]. Rheumatic heart disease may involve all cardiac valves, but 
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the mitral is most commonly affected. Stenosis is more commonly present at the mitral valve 
and regurgitation involving the aortic [49].
9.2. Echocardiographic diagnosis of rheumatic heart disease
The revised Jones Criteria [69] for diagnosis of ARF, importantly has now incorporated 
Doppler echo for both acute and chronic valvulitis. In the previous guideline (1992), cardiac 
involvement was based on clinical auscultation. Modern-era echo has been validated for diag-
nosis of subclinical carditis. Echo may either help confirm or exclude carditis when a murmur 
is present, or it may detect subclinical carditis. The most common cardiac changes are cardiac 
valve involvement (valvulitis) and may be accompanied by a pancarditis with or without a 
myopericarditis [69].
9.2.1. Echocardiographic diagnosis: Doppler haemodynamics and 2D features
With acute rheumatic mitral and aortic valvulopathy, functional and haemodynamic changes 
are readily diagnosed by Doppler echocardiography. The regurgitation must be demonstrated 
in at least 2 views with a peak jet velocity of >3 m/s, a pan systolic or diastolic jet respectively 
and a jet length of ≥2 cm for MR and ≥1 cm for AR. Morphological changes may or may not 
be present early during infection [69]. The morphological change(s) seen at the MV during 
acute valvulitis/carditis include: (i) annular dilatation, (ii) chordal elongation/rupture, (iii) 
leaflet prolapse and/or (iv) beading/nodular thickening of the leaflet tips. Chronic changes 
of the mitral valve apparatus include: (i) thickening of the leaflets/chords, (ii) chordal fusion, 
(iii) restriction of leaflet motion and/or (iv) calcification [69]. Acute and chronic aortic valve 
changes of rheumatic valvulitis/carditis demonstrated with 2-D echo include: (i) irregular 
and/or focal thickening of the leaflets, (ii) leaflet retraction/restriction with or without coapta-
tion defects and/or (iii) leaflet prolapse [69].
9.2.2. Risk of endocarditis
Incidence of IE in persons with RHD is 3.8–440 per 1000 patient-years [61]. Data published 
from the National Health Service in England [70], revealed a marginally lower incidence of 
3.05 cases per 1000 patient-years, compared with nonrheumatic valve disease at 2.73 per 1000 
patient-years in the same study. The incidence of IE in rheumatic mitral stenosis is estimated 
at 0.17 per 1000 patient-years. Severity of valvular haemodynamics in RHD and risk of IE is 
not well described.
10. Intravenous drug use
Intravenous drug use (IVDU), along with cardiac-devices, CHD and vascular access catheters, 
are the major risk factors for RSIE. Right-sided IE constitutes 5–10% of IE cases and approxi-
mately 90% of RSIE involves the TV [71]. Overall, IVDU use accounts for 5–10% of all cases of 
IE [3, 72]. The median age at time of infection is 30–40 years, not infrequently seen in patients 
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with human immunodeficiency virus (HIV). The majority of cases (right-sided > left-sided) 
are thought to involve structurally normal cardiac valves [8, 72]. Staphylococcus is the usual 
microorganism however infections are not infrequently polymicrobial [57]. Various fungi and 
pseudomonas are noteworthy for severe cases of IVDU-associated IE [8]. Interestingly, strep-
tococci and enterococci more commonly affect left-sided valves, often with underlying struc-
tural abnormalities [73, 74].
According to Mathew et al. [75], the overall incidence of left-sided cardiac involvement was 
similar to right-sided IE, with a minority involving both right and left-sided valves [75]. Others 
have reported a predominance of right-sided lesions in patients with IVDU [72, 76]. The  overall 
incidence of IE in IVDU is estimated at 0.7–20 cases per 1000 patient-years [74, 77].
The increased risk of IVDU patients acquiring IE is likely attributable to a multitude of fac-
tors. Proposed explanations include: (i) particulate matter injury to endothelium from sub-
stance injection, (ii) drug-induced thrombus formation and vasospasm, (iii) immune complex 
deposition on valves, (iv) altered host immune function, (v) frequent exposure to high volume 
bacterial inoculation, (v) increased prevalence of staphylococcal skin carriage, and (vi) sym-
pathomimetic -induced PHTN resulting in an increase in valvular regurgitation velocity and 
endothelial trauma. A preference for right-sided involvement of structurally normal valves 
may also be related to altered host and microorganism factors [71, 74, 78]. It is theorised par-
ticulate matter up to 8–10 μm in size can transit across the normal pulmonary vasculature and 
potentially traumatise left-sided valvular endothelium [75]. However, the relatively high prev-
alence of left-sided valve involvement in the IVDU cohort without apparent underlying valve 
disease, may not be completely explained by the above theories and warrants further research.
Transthoracic echocardiography is often very useful in IVDU patients for excluding predis-
posing underlying structural heart disease and providing confirmation of IE, especially for TV 
endocarditis. Patients with IVDU are often younger and with satisfactory acoustic windows. 
In addition, the TV is located anteriorly within chest, being in close proximity to the imaging 
transducer. The use of TOE is preferred for complicated cases of right and left-sided IE, such 
as periannular extension, prosthetic valves, nondiagnostic TTE, CHD and for excluding infec-
tion at other sites within the right heart, such as the Eustachian valve, atrial wall or vena cavae.
11. Prosthetic cardiac valves, devices and risk of endocarditis
11.1. Surgical valves
The estimated risk of prosthetic valve endocarditis (PVE) overall is 0.3–1.2% per patient 
year (3–12 per 1000 patient-years) [57]. Recent study data from the National Health Service 
in England [70] reported an incidence of 4.64 cases per 1000 patient-years. In a landmark 
early study from the 1980s, the risk for mechanical valve IE was shown to be higher in 
first 3 months post-surgery, whilst for porcine valves, the IE risk was higher >12 months. 
The cumulative risk by 5 years was not significantly different between mechanical and 
porcine [79].
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A large study recently published, incorporating contemporary valve data, has found bio-
prosthetic valves do carry a higher risk for IE than mechanical valves, with a multivariable-
adjusted hazard ratio of 1.65 (CI, 1.16–2.37) for early (<12 month) and 1.53 (CI, 1.25–1.86) 
for late (>12 months) IE. The crude incidence rates were 11.7 vs. 7 per 1000 patient-years for 
early IE and 6.0 vs. 4.3 per 1000 patient-years at 1–5 years (post-surgery) for bioprosthetic 
and mechanical valves, respectively. Similar rates were seen out to 15 years of follow-up in 
both groups. The overall combined incidence for PVE was 0.57% (5.7/1000) per patient-year 
[80]. It was suggested structural deterioration of prosthetic valves is a contributing risk 
factor, but this requires further investigation. Another study found a higher risk of IE with 
bioprosthetic over mechanical AVR, where the incidence of re-hospitalisation for IE was at 
2.2% versus 1.4%, over 12 years follow-up, with adjusted hazard ratio of 1.6 (CI, 1.31–1.94). 
This difference was seen across all groups, except those aged 75–80 years and patients with 
renal failure [80].
11.2. Valve repairs
Valve repairs with prosthetic material carry a reported incidence of 4.71 cases per 1000 patient 
years [70]. In a pooled analysis (24 studies), recurrence of IE after mitral valve repair ver-
sus surgical replacement was 1.8% compared to 7.3% (p 0.0013), with a mean follow-up of 
approximately 50 months [81].
11.3. Transcatheter valves
The incidence of IE in transcatheter aortic valve replacement (TAVR) is similar to surgically 
placed prosthetic valves. There is no reported significant difference between self-expanding 
and balloon-expanding IE rates. Residual moderate or severe regurgitation was associated 
with higher rates of IE at 16.3 per 1000 patient-years versus 9.3 per 1000 patient-years for mild 
or no aortic regurgitation [82].
For pulmonary transcatheter valve (Medtronic MelodyTM), one study [83] reported a rate of IE 
of 3% per patient-year for a median follow-up of approximately 2 years. With regard to valved-
conduits, the incidence of IE with RVOT homografts was lower at 0.8% per patient-year compared 
to Contegra-Melody conduit rate of 2.7–3.0% per patient-year. In patients with an infected Melody 
valve, 4/8 had a peak gradient >40 mmHg, whilst only 5/99 in the non-IE group had a similar 
gradient (p < 0.05) [83]. This suggests a possible increased risk of IE with residual post-procedural 
gradients, but numbers are insufficient and further studies are required to confirm or refute this 
assertion.
11.4. Device-related endocarditis
Ventricular assist devices (VADs) carry an incidence of IE of 5.8 cases per 1000 patient-years 
[70]. In one study investigating VAD infections, the following rates (cases per 100 LVAD-
years) were found: i) all infection types –32.8 (CI, 26.7–39.9), ii) IE 1.6 (CI, 0.5–3.8) and iii) 
bloodstream – VAD-related, 7.5 (CI, 4.7–11.2) [84].
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Implantable pacemakers (PPM) and cardiac defibrillators (ICD) have a reported incidence of 
IE ranging from 0.68–1.9 cases per 1000 patient-years [57, 70]. Cardiac device-related infective 
endocarditis accounts for 10–23% of device infections [85]. Numerous risk factors have been 
identified, including previous device-related infection, however information on risk related 
to underlying structural cardiac or TV pathology is uncertain. From the ICE-PICS data [86], 
6.4% of all cases of IE were CDRIE. Over one-third of cases had associated valvular involve-
ment, most commonly the tricuspid valve.
11.5. Recurrent native and prosthetic valve infective endocarditis
One of the most important cardiac risk factors for endocarditis is a prior history of IE. In 
the ICE- PCS cohort, recurrent IE occurred in 4.8% of patients, given an odds ratio of 2.8 
(CI, 1.5–5.1) [87]. This is concordant with findings from other published studies with rates 
between 3.3 and 11.7% [88, 89]. In a recent study, the risk for recurrent IE was 14.36 per 1000 
patient-years [70]. In a different study, the risk of recurrence (in patient-years) was estimated 
as follows: (i) history of previous IE, 7.4 per 1000, (ii) prosthetic valve surgery for native valve 
IE, 6.3 per 1000 and, (iii) prosthetic valve surgery for prosthetic valve IE, 21.6 per 1000 [61]. In 
a meta-analysis comparing biological versus mechanical valve for IE surgery, recurrence of 
IE in mechanical valves was 3–9% and for biological valves 7–29% [90] . Other studies have 
found equal rates of reinfection of bioprosthetic and mechanical valves.
Renzulli et al. [91], interestingly reported there was no association with previous perivalvular 
extension and recurrent risk [91]. In a study focussing on aortic homografts, Flameng et al. 
[92] found the recurrence rate of IE was relatively low at 7% at a mean follow-up of 8 ± 5 years. 
A significant downside is the high rate of structural deterioration of aortic homografts, with 
a rate of 40% at 10 years [92].
Shimokawa et al. [93] reviewed long term outcomes of mitral valve repair following IE in 
patients with prolapse and found good outcomes when compared with repair for degenera-
tive MVP without IE. In this study, there were no recurrences of IE [93]. In another meta-
analysis, comparing MV replacement with MV repair in the setting of IE, the 5 year risk of 
recurrent IE was favourable in the repair group with OR 0.39 (0.10–1.58) [94].
12. Conclusion
The three main categories of cardiac disease predisposing to infective endocarditis are degen-
erative valve disease, congenital heart disease and less commonly in high-income countries, 
rheumatic heart disease. The changing epidemiology has been associated with an ageing popu-
lation, increased prevalence of prosthetic valves, devices and shunts, and health-care exposure. 
This chapter has outlined the underlying pathology, risks and echocardiographic predictors for 
IE associated with a selection of lesion-specific cardiac pathologies. The chapter also addressed 
the observation of structurally ‘normal’ cardiac valves accounting for a rising proportion of 
IE cases. Whether this relates to microorganism virulence, host factors, early structural and 
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functional changes associated with degenerative valve disease, or a combination of all of the 
above, is unproven. Only further focused research using modern-era high resolution imaging 
and clinicopathological correlation, will provide new insight into this interesting question.
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